Beta Drugs Limited H1 FY26 Concall Decoded: From Methotrexate to Meso-Fills — Pharma’s New Multiverse
Just when the market thought oncology was Beta’s only playground, CMD Rahul Batra opened the call with a Diwali gift — migration to NSE’s main board in ten days. Not bad for a company juggling cytotoxics, biosimilars-in-waiting, and now… Italian beauty fillers. Who says science can’t be glamorous? But the street’s celebration paused when growth clocked 13% instead of the promised 25%. Cue CFO’s classic — “rain, audits, and product mix.” Still, margins rose, derma turned profitable, and Beta is filing dossiers faster than influencers post reels. Stick around — the pharma plot thickens.
At a Glance
Revenue ₹204 Cr (↑13% YoY): Rain delays met Mexico audits — double trouble, same result.
EBITDA ₹47 Cr (↑17% YoY): Margins ticked up to 23.08%; CFO swears it’s not Excel magic.
PAT ₹28.7 Cr (↑18% YoY): Debenture interest excluded — fine print matters.
Derma EBITDA positive: Finally, skincare isn’t just vanity, it’s profit.
Stock Mood: Investors applying Italian fillers to smoothen growth wrinkles.
Management’s Key Commentary
“We’ve got principal approval to migrate to NSE’s main board in 10 days.” (Translation: The small-cap tag is finally too small for our ambitions.) 🎉
“EBITDA margins improved from 22.36% to 23.08%.” (CFO whisper: Don’t ask how, just clap.)
“Derma division turned EBITDA positive — ₹11.3 lakh profit.” (Baby steps, but hey, skincare pays bills now.)
“Filed 80 dossiers, got 43 new approvals — global hustle in motion.” (If paperwork were power, Beta could light up Gurgaon.)
“Acquired new intermediate plant to reduce China dependency.” (Swadeshi chemistry meets import paranoia.) 🇮🇳
“Europe audit between Jan–Mar 2026; we’ll be first cytotoxic suspension plant inspected.” (Translation: Europe’s regulators, get your hazmat suits ready.)
“Filed India’s first NDDS for Methotrexate oral solution.” (Three years of effort — finally, a mouthful of achievement.)
